4.4 Review

Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells

期刊

CURRENT CANCER DRUG TARGETS
卷 9, 期 3, 页码 320-340

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800909788166600

关键词

Apoptosis; Bcl-2; p53; TNF alpha; TRAIL; survivin; clinical trials

类别

资金

  1. Ministerio de Sanidad y Consumo [FIS 05/0689, FIS 06/1226, FIS 08/1085, ISCIII-RETIC RD06/0020/0097]
  2. Fundacion Medica Mutua Madrilena

向作者/读者索取更多资源

Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLXL, Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-kappa B etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据